From L-R: Tune Therapeutics' CSO Derek Jantz, CFO Akira Matsuno and co-founder Charles Gersbach
Exclusive: Bucking gene-editing downturn, Tune raises $175M to bring epigenetic editing to clinic
In genetic medicine, a drumbeat of layoffs and pipeline cuts has replaced the excitement of just a few years ago, when fresh financing rounds were …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
